Product correctly added to cart.

discount label
JNJ16259685
View 3D

Biosynth logo

JNJ16259685

CAS: 409345-29-5

Ref. 3D-JRA34529

25mgTo inquire
50mgTo inquire
100mgTo inquire
Estimated delivery in United States, on Friday 17 Jan 2025

Product Information

Name:
JNJ16259685
Synonyms:
  • JNJ 16259685
  • (3,4-Dihydro-2H-pyrano[2,3-b]quinolin-7-yl)(cis-4-methoxycyclohexyl)methanone
  • Methanone, (3,4-dihydro-2H-pyrano[2,3-b]quinolin-7-yl)(cis-4-methoxycyclohexyl)-
Description:

JNJ16259685 is a metabotropic glutamate receptor antagonist that was developed as a potential drug target for the treatment of eye disorders. JNJ16259685 is an experimental model for pharmacological treatment of neuronal death and degeneration, and has been shown to decrease locomotor activity in experimental models. JNJ16259685 binds to the metabotropic glutamate receptor type 1 (mglur1) with high affinity and blocks the binding of glutamate to mglur1, which prevents neuronal death. JNJ16259685 has also been shown to be effective against ryanodine receptor-associated diseases by blocking the release of calcium from intracellular stores.

Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
Biosynth
Long term storage:
Notes:

Chemical properties

Molecular weight:
325.4 g/mol
Formula:
C20H23NO3
Purity:
Min. 95%
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:

Hazard Info

UN Number:
EQ:
Class:
H Statements:
P Statements:
Forbidden to fly:
Hazard Info:
Packing Group:
LQ:

Technical inquiry about: 3D-JRA34529 JNJ16259685

Please use instead the cart to request a quotation or an order

If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.

* Mandatory fields.
Welcome to CymitQuimica!We use cookies to enhance your visit. We do not include advertising.

Please see our Cookies Policy for more details or adjust your preferences in "Settings".